Sepsis Research Analysis
Q2 2026 sepsis research converged on host-directed control of inflammation and injury, rapid resistance diagnostics, and organ-specific metabolic therapy. April inaugurated an inflammasome-focused wave with an LRR-binding NLRP3 inhibitor (LOC14) and dual NLRP3–NCF1 redox targeting, which set the stage for May’s repurposed NLRP3 inhibitor ciclopirox with immediate translational potential. Cross-cutting immunometabolism advanced through discovery that itaconate alkylates AIM2 to trigger macrophage